Innovation for Patients Driven by

The Potential to Forever Change How Cancer is Treated

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR TTM) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T (Auto CAR TTM) therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Learn More

Accelerating an Expansive Portfolio

We are advancing our AlloCAR TTM portfolio acquired from Pfizer, which includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to clinical candidates ALLO-501 and UCART19.

Allogene initiated its Phase 1 ALPHA study of ALLO-501 in 1H 2019 to assess safety and tolerability of ALLO-501 and ALLO-647, our proprietary anti-CD52 monoclonal antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Servier is the sponsor of the UCART19 program, which is currently in Phase 1 for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

Learn More

Led by a Veteran Team

Our world-class management team has significant experience in cell therapy. Allogene co-founders include Dr. Arie Belldegrun and Dr. David Chang, who developed one of the first CAR T cell therapies approved by the U.S. Food and Drug Administration. The team has unparalleled scientific, clinical and regulatory expertise, and a track record of success.

Learn More

Latest News

Aug 07
2019

Allogene Therapeutics Reports Second Quarter 2019 Financial Results

Learn More >
Aug 05
2019

Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer

Learn More >
Jul 29
2019

Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019

Learn More >
Jun 04
2019

Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy

Learn More >
May 29
2019

Allogene Therapeutics Announces June 2019 Investor Conference Schedule

Learn More >
May 07
2019

Allogene Therapeutics Reports First Quarter 2019 Financial Results

Learn More >
May 01
2019

Allogene Therapeutics Announces Expansion of Scientific Advisory Board

Learn More >
Apr 30
2019

Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019

Learn More >
Apr 15
2019

Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma

Learn More >
Apr 03
2019

Allogene Therapeutics Announces April 2019 Investor Conference Schedule

Learn More >
Apr 01
2019

Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting

Learn More >
Mar 08
2019

Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Learn More >
Feb 27
2019

Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019

Learn More >
Feb 20
2019

Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies

Learn More >
Feb 05
2019

Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule

Learn More >
Jan 28
2019

Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy

Learn More >
Dec 19
2018

Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Learn More >
Dec 03
2018

Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Learn More >
Dec 03
2018

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

Learn More >
Nov 05
2018

Allogene Therapeutics Announces November 2018 Investor Conference Schedule

Learn More >
Nov 01
2018

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

Learn More >
Oct 15
2018

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Learn More >
Oct 10
2018

Allogene Therapeutics Announces Pricing of Initial Public Offering

Learn More >
Sep 27
2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

Learn More >
Sep 14
2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Learn More >
Sep 06
2018

Allogene Therapeutics Completes a $120 Million Private Financing

Learn More >
Aug 28
2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality August 14, 2018

Learn More >
Aug 14
2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

Learn More >
Jul 10
2018

Allogene Therapeutics Announces Scientific Advisory Board

Learn More >
Jun 18
2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

Learn More >
Jun 12
2018

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

Learn More >
Jun 04
2018

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

Learn More >
May 30
2018

Allogene Therapeutics Announces Board of Directors

Learn More >
May 14
2018

Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Learn More >
Apr 09
2018

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

Learn More >
Apr 03
2018

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Learn More >
Apr 03
2018

Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Learn More >